Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
Moderna, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRNA
08:13am, Sunday, 15'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 15, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, f
NEW YORK CITY, NY / ACCESSWIRE / September 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Modern
World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna
03:00am, Sunday, 15'th Sep 2024
Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna in the second quarter.
Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join - Contact Levi & Korsinsky
09:01pm, Saturday, 14'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 14, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, f
The Schall Law Firm Wants Investors To Assist The Schall Law Firm In A Securities Fraud Case Against Moderna, Inc.
11:00am, Saturday, 14'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
09:15am, Saturday, 14'th Sep 2024
Analyzing the board of directors is a quick way to assess people power. Scientific advisory boards are easier to analyze than they might seem.
NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
04:20am, Saturday, 14'th Sep 2024
Moderna's shares climbed in the first half of the year, as it scored victories with a product approval and solid clinical trial results. This week the biotech surprised investors with some changes to
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
06:34pm, Friday, 13'th Sep 2024
Thursday, Moderna Inc MRNA unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, enabling a focus on ten prioritized products.
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, f
Why Moderna's delayed break-even goal may not even be possible
05:58pm, Friday, 13'th Sep 2024
Shares of Moderna (MRNA) have been falling this week after the biotech company pushed back its break-even goal by two years and predicted 2025 sales to come below its forecast for the current year. Mo
Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut
04:07pm, Friday, 13'th Sep 2024
Shares of Moderna (MRNA) fell for the second day in a row after the company said it would slash its research and development expenditures.
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
04:06pm, Friday, 13'th Sep 2024
As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.
Moderna, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRNA
12:15pm, Friday, 13'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, f
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA) and certain officer
